Prostate Cancer News and Research

Latest Prostate Cancer News and Research

New findings from STELARA psoriasis clinical trial to be presented at 22nd World Congress of Dermatology

New findings to be presented from pooled analyses of the STELARA psoriasis clinical development program showed that the safety profile of STELARA and rates of adverse events remained consistent and stable over time in adults with moderate to severe plaque psoriasis receiving up to four years of treatment.

25 May 2011

Brisk walking may delay or even prevent progression of prostate cancer in men

Men with prostate cancer can improve their outcomes if they walk briskly for at least three hours a week following their diagnosis, according to a recent study in Cancer Research, a journal of the American Association for Cancer Research.

25 May 2011

Some African descent men may have higher genetic risk of developing prostate cancer

Some men of African descent may have a higher genetic risk of developing prostate cancer, according to research conducted at the Keck School of Medicine of the University of Southern California.

24 May 2011

Long-term, regular acetaminophen use may be associated with lower prostate cancer risk

A new study from American Cancer Society researchers finds use of 30 tablets a month or more of acetaminophen for five or more years was associated with an estimated 38% lower risk of prostate cancer. The study appears in Cancer Epidemiology, Biomarkers and Prevention and is one of only two studies of prostate cancer to date that have examined the association with acetaminophen use that was both long-term and regular.

24 May 2011

Journal of Clinical Oncology publishes Exelixis' cabozantinib phase 1 trial results in lymphoma

Exelixis, Inc. today announced the results of the phase 1 clinical trial of cabozantinib in patients with advanced solid tumors or lymphoma have been published in the current issue of the Journal of Clinical Oncology.

24 May 2011

'Turkey tail' mushroom effectively suppresses prostate tumour development

A mushroom used in Asia for its medicinal benefits has been found to be 100 per cent effective in suppressing prostate tumour development in mice during early trials, new Queensland University of Technology (QUT) research shows.

23 May 2011

Stopping prostate cancer cells from 'bulking up' with nutrients blocks spread of disease

Cancer Research UK scientists have discovered that stopping prostate cancer cells from 'bulking up' with nutrients reduces the spread of the disease and tumour size, according to research published today in EMBO Journal.

21 May 2011

EMA CHMP recommends positive opinion for marketing authorization of Amgen's XGEVA

Amgen today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended a positive opinion for the marketing authorization of XGEVA (denosumab) for the prevention of skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumors.

20 May 2011

Longer looks: Tough health care questions for GOP presidential contenders; Robotics help spike use of prostate treatment

For my money, the most interesting thing about Mitt Romney's health-care speech last week wasn't his struggle to defend Romneycare and distance it from Obamacare, but the largely hostile reception of the speech from the right.

20 May 2011

Advantagene reaches SPA agreement with FDA for ProstAtak Phase 3 trial to prevent prostate cancer recurrence

Advantagene, Inc., a Massachusetts-based biopharmaceutical company, announced today that it reached an agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment (SPA) for a pivotal Phase 3 clinical trial of ProstAtak™, its lead agent for patients with newly diagnosed prostate cancer.

19 May 2011

Mitomics enters licensing agreement with QDx Pathology Services for QPredict Prostate Mitomic Test

Mitomics, world leader in the research and development of mitochondrial genome-based products, today announced it has entered into a non-exclusive licensing agreement with QDx Pathology Services to develop, market and process the QPredict™ Prostate Mitomic Test.

19 May 2011

New denosumab Phase III trial data in high-risk prostate cancer presented at AUA conference

Data on the use of denosumab (Xgeva) to improve bone metastases-free survival in men with high-risk prostate cancer was presented at the American Urological Association conference today for the first time.

18 May 2011

Bayer HealthCare to present results on investigational oncology compounds at ASCO annual meeting

Bayer HealthCare Pharmaceuticals, Inc. announced today that data evaluating several of its investigational oncology compounds will be presented in a scientific forum at the 2011 Annual Meeting of the American Society of Clinical Oncology, June 3-7, in Chicago, IL.

18 May 2011

Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer

Amgen today announced primary results of a pivotal Phase 3 trial demonstrating that XGEVA significantly increased bone metastasis-free survival for more than four months in men with castrate-resistant metastatic prostate cancer that has not yet spread to bone.

18 May 2011

Coffee reduces prostate cancer risk

In the 20-year study of almost 50,000 men, researchers noted that those who drank at least six cups a day were 20 per cent less likely to get prostate cancer than those who never took coffee. Strikingly, they were 60 per cent less likely than the non-coffee drinkers to die of the disease. The researchers also say that decaffeinated coffee is just as effective.

17 May 2011

New A+PSA assay more accurately detects prostate cancer

A new test for prostate cancer that measures levels of prostate specific antigen (PSA) as well as six specific antibodies found in the blood of men with the disease was more sensitive and more specific than the conventional PSA test used today, according to a study by researchers at UCLA's Jonsson Comprehensive Cancer Center.

17 May 2011

CytRx sells global rights of molecular chaperone assets to Orphazyme

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that it has sold the worldwide rights to its molecular chaperone assets to privately-held, Copenhagen, Denmark-based Orphazyme ApS.

17 May 2011

Calypso System can precisely deliver radiation in post-prostatectomy patients

Calypso Medical Technologies, Inc., developer of GPS for the Body® technology used for the precise tracking of cancerous tumors during radiation therapy, is exhibiting at the American Urological Association Annual Meeting (booth 4337) and will discuss recent clinical findings suggesting that the Calypso® System can be used to more precisely deliver radiation in post-prostatectomy patients.

16 May 2011

IsoRay third fiscal quarter sales increase 17%

IsoRay Inc., announced financial results for the third fiscal quarter ended March 31, 2011 underscoring significant improvements in quarterly sales revenue growth both sequentially and in the prior year quarter. Sales increased 17% in the period with the Company posting a 581% gain in gross profit compared to the prior year third quarter.

16 May 2011

Obese men may face high risk of prostate cancer progression

Even when treated with hormone therapy to suppress tumor growth, obese men face an elevated risk of their prostate cancer worsening, researchers at Duke University Medical Center have found.

16 May 2011

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

New findings from STELARA psoriasis clinical trial to be presented at 22nd World Congress of Dermatology

Brisk walking may delay or even prevent progression of prostate cancer in men

Some African descent men may have higher genetic risk of developing prostate cancer

Long-term, regular acetaminophen use may be associated with lower prostate cancer risk

Journal of Clinical Oncology publishes Exelixis' cabozantinib phase 1 trial results in lymphoma

'Turkey tail' mushroom effectively suppresses prostate tumour development

Stopping prostate cancer cells from 'bulking up' with nutrients blocks spread of disease

EMA CHMP recommends positive opinion for marketing authorization of Amgen's XGEVA

Longer looks: Tough health care questions for GOP presidential contenders; Robotics help spike use of prostate treatment

Advantagene reaches SPA agreement with FDA for ProstAtak Phase 3 trial to prevent prostate cancer recurrence

Mitomics enters licensing agreement with QDx Pathology Services for QPredict Prostate Mitomic Test

New denosumab Phase III trial data in high-risk prostate cancer presented at AUA conference

Bayer HealthCare to present results on investigational oncology compounds at ASCO annual meeting

Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer

Coffee reduces prostate cancer risk

New A+PSA assay more accurately detects prostate cancer

CytRx sells global rights of molecular chaperone assets to Orphazyme

Calypso System can precisely deliver radiation in post-prostatectomy patients

IsoRay third fiscal quarter sales increase 17%

Obese men may face high risk of prostate cancer progression

What to know about prostate cancer eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in